# Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

> **NCT02831751** · PHASE2 · COMPLETED · sponsor: **Medicago** · enrollment: 1001 (actual)

## Conditions studied

- Virus Diseases
- RNA Virus Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** 30 µg/strain of Quadrivalent VLP Vaccine
- **BIOLOGICAL:** 60 µg/strain of Quadrivalent VLP Vaccine
- **BIOLOGICAL:** FluLaval® Tetra (15 µg/strain)
- **BIOLOGICAL:** Fluzone® High-Dose (60 µg/strain)

## Key facts

- **NCT ID:** NCT02831751
- **Lead sponsor:** Medicago
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-07
- **Final completion:** 2017-01
- **Target enrollment:** 1001 (ACTUAL)
- **Last updated:** 2019-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831751, "Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02831751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*